Tag Archives: Therapix Biosciences

Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

TEL AVIV, Israel, Dec. 4, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of..

4 Dec

Blunt Newswire

Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center

TEL AVIV, Israel, Oct. 30, 2017 /PRNewswire/ — Therapix Biosciences Ltd. (NASDAQ: TRPX) (“Therapix” or the “Company”), a specialty, clinical-stage pharmaceutical company focusing on..

30 Oct

Blunt: Curating the Cannabis Content you Need the Most

Tag Archives: Therapix Biosciences

Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

Therapix Biosciences Initiates Non-clinical Studies for its Antibacterial Program in Collaboration With the Weizmann Institute of Science and Tel Aviv Sourasky Medical Center

Subscribe to Our Post Alerts

Good SEO Starts Here

Most Popular

Blunt Newswire

UPCOMING EVENTS

Cannabis Jobs

About Blunt Network

We Are Social

Blunt: Curating the Cannabis Content you Need the Most